Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support
Szkukalek, J.; Dóczi, R.; Dirner, A.; Boldizsár, Á.; Varga, Á.; Déri, J.; Lakatos, D.; Tihanyi, D.; Vodicska, B.; Schwáb, R.; Pajkos, G.; Várkondi, E.; Vályi-Nagy, I.; Valtinyi, D.; Nagy, Z.; Peták, I. Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support. Diagnostics 2021, 11, 1850. https://doi.org/10.3390/diagnostics11101850
Szkukalek J, Dóczi R, Dirner A, Boldizsár Á, Varga Á, Déri J, Lakatos D, Tihanyi D, Vodicska B, Schwáb R, Pajkos G, Várkondi E, Vályi-Nagy I, Valtinyi D, Nagy Z, Peták I. Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support. Diagnostics. 2021; 11(10):1850. https://doi.org/10.3390/diagnostics11101850
Chicago/Turabian StyleSzkukalek, Judita, Róbert Dóczi, Anna Dirner, Ákos Boldizsár, Ágnes Varga, Júlia Déri, Dóra Lakatos, Dóra Tihanyi, Barbara Vodicska, Richárd Schwáb, Gábor Pajkos, Edit Várkondi, István Vályi-Nagy, Dorottya Valtinyi, Zsuzsanna Nagy, and István Peták. 2021. "Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support" Diagnostics 11, no. 10: 1850. https://doi.org/10.3390/diagnostics11101850